Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUMOROID pilot study of intratumoral osimertinib concentrations in colorectal cancer metastases
NL-OMON51641Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of osimertinib in colorectal cancer (CRC) (2 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Intratumoral osimertinib concentration in peritoneal metastasis and liver metastasis. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON51641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51641.